{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:43:35Z","timestamp":1777934615212,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>Enfortumab vedotin (EV) is a novel treatment option for patients with advanced\/metastatic urothelial carcinoma who have progressed after chemotherapy and immunotherapy. Two patients at two different New England tertiary cancer care centers were treated with EV while concurrently receiving hemodialysis (HD), where a complete response to EV in both patients was noted. The use of EV in patients requiring HD is extrapolated from the available pharmacokinetic and pharmacodynamic literature on monoclonal antibodies in patients requiring HD. There is a paucity of data for the use of antibody-drug conjugates like EV in patients needing dialysis.<\/jats:p>","DOI":"10.1177\/10781552241237752","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T11:43:11Z","timestamp":1710243791000},"page":"941-944","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1192-0825","authenticated-orcid":false,"given":"Harshit","family":"Khosla","sequence":"first","affiliation":[{"name":"Saint Vincent Hospital, Worcester, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sita","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Boston Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Jin","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School, Worcester, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gretchen","family":"Gignac","sequence":"additional","affiliation":[{"name":"Boston Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kriti","family":"Mittal","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School, Worcester, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Patel","sequence":"additional","affiliation":[{"name":"Boston Medical Center, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"bibr1-10781552241237752","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"bibr2-10781552241237752","volume":"2023","author":"Powles TB","journal-title":"Ann Oncol"},{"key":"bibr3-10781552241237752","volume":"11","author":"Hatakeyama S","year":"2016","journal-title":"PLoS One"},{"key":"bibr4-10781552241237752","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13091339"},{"key":"bibr5-10781552241237752","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313"},{"key":"bibr6-10781552241237752","first-page":"1","volume":"13","author":"Waldmann TA","year":"1969","journal-title":"Prog Allergy [Internet]"},{"key":"bibr7-10781552241237752","unstructured":"Drug Approval Package: PADCEV enfortumab vedotin-ejfv. Retrieved September 12, 2023, from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761137Orig1s000TOC.cfm (n.d.)."},{"key":"bibr8-10781552241237752","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100314"},{"key":"bibr9-10781552241237752","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.892793"},{"key":"bibr10-10781552241237752","first-page":"423","volume":"16","author":"Isoda B","year":"2023","journal-title":"Case Rep Oncol"},{"key":"bibr11-10781552241237752","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.07.443"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241237752","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241237752","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241237752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:37Z","timestamp":1777688977000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241237752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1177\/10781552241237752"],"URL":"https:\/\/doi.org\/10.1177\/10781552241237752","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]}}}